Diabetes Mellitus, Type 2
Conditions
Brief summary
This study will look at how a mobile based app called 'Dose Check' used along with Xultophy® helps the treatment in participants with type 2 diabetes mellitus (T2DM). Participants will get Xultophy® as prescribed by study doctor or will continue already prescribed treatment with Xultophy®. Participants will also be prescribed to use Dose Check app by study doctor. Participants will be asked to install the Dose Check app in their mobile phone, which will be supported with the correct dose of Xultophy®. The study will last for about 6 to 8 months.
Interventions
DRUGIDegLira
Pre-filled pen injection.
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * Male or female, age above or equal to 21 years at the time of signing informed consent. * Diagnosed with T2DM \>=12 weeks prior to signing consent. * The decision to initiate treatment with commercially available Dose Check app as a part of treatment along with Xultophy® as per the local label has been made by the patient and the treating physician before and independently from the decision to include the participant in this study. * Participants who are insulin naive (including the following situations: i. already on treatment with Xultophy® at V1 for less than or equal to (\<=) 12 months and for \<= 15 dose steps and ii. short-term insulin use for acute illness for a total of \<14 days) * Available HbA1c value \<=12 weeks prior to the 'Informed consent and initiation of Dose Check app visit' (V1) or HbA1c measurement taken in relation with the 'Informed consent and initiation of Dose Check app visit' (V1), if in line with local clinical practice. * Willingness to continue using the Dose Check app on a compatible smartphone according to the intended use for the entire duration of the study.
Exclusion criteria
* Previous participation in this study. Participation is defined as having signed informed consent in this study. * Women known to be pregnant or breastfeeding, or women planning to become pregnant during the conduct of the study. * Treatment with any investigational drug or software as a medical device (SaMD) within 30 days prior to enrolment into the study. * Diagnosed with type 1 diabetes mellitus. * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. * Hypersensitivity to the active substance or any of the excipients as specified in the Xultophy® local label.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Participant downloaded and actively used the app (Yes/No) | From baseline (week 0) to end of the study (EOS) visit (week 26) | Measured as count of participants. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Participants reaching individual HbA1c target set by physician | At EOS visit (week 26) | Measured as count of participants (yes/no). |
| Participants reaching physician set individual fasting blood glucose (FBG) target | From baseline (week 0) to EOS visit (week 26) | Measured as count of participants (yes/no). |
| Change in glycated haemoglobin (HbA1c) | From baseline (week 0) to EOS visit (week 26) | Measured as percentage (%) points. |
| Participants achieving target level FBG according to clinical guidance | From baseline (week 0) to EOS visit (week 26) | Measured as count of participants (yes/no). |
| Change in laboratory measured FPG | From baseline (week 0) to EOS visit (week 26) | Measured in milligrams per deciliter (mg/dL). |
| Time to physician set individual FBG target from first reported FBG | From baseline (week 0) to EOS visit (week 26) | Measured in number of weeks. |
Countries
Italy
Outcome results
None listed